Qualigen (QLGN) Jumps 18% After Faraday-led $41M PIPE Hands FFAI ~55% Control as QLGN Rebrands to CXC10

Qualigen Therapeutics (NASDAQ:QLGN) jumped about 18% on Tuesday after the company confirmed it closed a $41 million PIPE financing that was led by Faraday Future Intelligent Electric (NASDAQ:FFAI). The deal is a clear pivot: Qualigen plans to rebrand and build a crypto- and Web3-focused business under the name CXC10.

The headline numbers are straightforward. Faraday put in roughly $30 million across common and preferred shares and will hold about 55% of pro forma beneficial ownership. YT Jia, Faraday's founder and global co-CEO, added roughly $4 million of his own capital and agreed to a two‑year voluntary lockup that represents roughly 7% ownership. The financing package also lists participation from several blockchain and venture backers.

Management and governance shifted fast. Faraday's president, Jerry Wang, is stepping in as co‑CEO of Qualigen, while YT Jia will serve as chief advisor. Faraday's CFO, Koti Meka, has been tapped as Qualigen's CFO. That's not a light touch - it's essentially new control and a management team aligned with the new strategy.

On what they plan to build: the company says most of the proceeds will seed CXC10, an effort centered on three lines - a "Crypto 10" value anchor, an AI-driven crypto trading agent called BesTrade, and ecosystem tokens including a proposed C10 stablecoin - while keeping the legacy business running.

For traders, several implications jump out. First, a pro‑forma 55% ownership by the new investor effectively hands control to Faraday, which changes the governance math and the likely strategic priorities going forward. Second, a PIPE that large delivered quickly after the announcement tends to compress available float in the short term but usually dilutes existing holders when the paper converts or preferred shares convert down the line. Third, the two‑year lockup by a principal investor reduces immediate selling pressure from that pocket, but it doesn't remove other sources of volatility.

There's also a mismatch risk: Qualigen's historical identity as a therapeutics company is being replaced by a crypto playbook. That kind of radical pivot can attract fresh speculative interest - hence the intraday pop - but it also brings a new set of regulatory, execution, and market risks. Preferred stock terms, liquidation preferences and any conversion mechanics in the PIPE matter a lot here; they determine who gets economic priority if things go sideways. The company hasn't published those contract details in the announcement, so that's a watch item.

Near-term catalysts that could move the shares: rollout details for CXC10, product demos or timelines for BesTrade, tokenomics for the C10 stablecoin, and any filings that clarify the terms of the preferred stock and pro‑forma cap table. Don't forget the calendar effects - quarterly reports and any SEC commentary about the pivot could swing sentiment sharply.

Bottom line: this is a big strategic U‑turn financed by a single lead investor who now holds the keys. That explains the rally, but it also sets up a very different risk-reward profile than the name had a few months ago. Will QLGN end up trading as a crypto play under the CXC10 brand or revert to its old identity? That's the storyline now.